News
RVVTF
0.020
NaN%
--
Weekly Report: what happened at RVVTF last week (0921-0925)?
Weekly Report · 3d ago
Weekly Report: what happened at RVVTF last week (0914-0918)?
Weekly Report · 09/21 09:50
Revive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases
TipRanks · 09/16 10:30
Revive Therapeutics to expand bucillamine IP, Orphan Drug portfolio
TipRanks · 09/15 13:40
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Barchart · 09/15 08:35
Weekly Report: what happened at RVVTF last week (0907-0911)?
Weekly Report · 09/14 09:53
Weekly Report: what happened at RVVTF last week (0831-0904)?
Weekly Report · 09/07 09:49
Weekly Report: what happened at RVVTF last week (0824-0828)?
Weekly Report · 08/31 09:54
Weekly Report: what happened at RVVTF last week (0817-0821)?
Weekly Report · 08/24 09:54
Revive Therapeutics Moves to Settle Trade Debt Through Share Issuance
TipRanks · 08/19 19:07
Revive Therapeutics Announces Proposed Shares for Debt Settlement
Barchart · 08/19 13:35
Revive Therapeutics Sets Bucillamine-Led Strategy for Biodefence and Pandemic Countermeasures
TipRanks · 08/19 13:07
Revive outlines strategy for biodefense, pandemic preparedness therapeutics
TipRanks · 08/19 12:45
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
Barchart · 08/19 07:40
Weekly Report: what happened at RVVTF last week (0810-0814)?
Weekly Report · 08/17 09:55
Revive Therapeutics Grants 15.5 Million Stock Options to Key Team Members
TipRanks · 08/14 23:02
Revive Therapeutics Reports Grant of Options
Barchart · 08/14 17:50
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Barchart · 08/12 06:55
Weekly Report: what happened at RVVTF last week (0803-0807)?
Weekly Report · 08/10 09:51
More
Webull provides a variety of real-time RVVTF stock news. You can receive the latest news about Revive Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About RVVTF
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The Company is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).